Rapid and long-term response of pulmonary pleomorphic carcinoma to nivolumab

Satoru Senoo, Takashi Ninomiya, Go Makimoto, Kazuya Nishii, Hirohisa Kano, Hiromi Watanabe, Yusuke Hata, Toshio Kubo, Takehiro Tanaka, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)


Pulmonary pleomorphic carcinoma (PPC) is a rare very aggressive subtype of non-small cell lung cancer. We herein report a case of PPC that showed a rapid response to nivolumab. The patient, whose multiple tumors had progressed very aggressively, was treated with nivolumab, an anti-programmed cell death-1 (PD-1) antibody. The tumors dramatically shrank after one cycle of nivolumab. The tumors were positive for programmed cell death ligand 1 (PD-L1). An immunohistochemical analysis revealed numerous PD-1+, CD68+ and CD206+ macrophages. This PD-1 antibody may be a good treatment option, especially in tumors that express PD-L1 and which show PD-1+ macrophage infiltration.

Original languageEnglish
Pages (from-to)985-989
Number of pages5
JournalInternal Medicine
Issue number7
Publication statusPublished - 2019


  • FGFR
  • Immune checkpoint inhibitor
  • PD-1
  • PD-L1
  • Pulmonary pleomorphic carcinoma

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Rapid and long-term response of pulmonary pleomorphic carcinoma to nivolumab'. Together they form a unique fingerprint.

Cite this